For research use only. Not for therapeutic Use.
Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.
Results show that Isoxsuprine hydrochloride inhibits circular chemorepellent induced defect (CCID) formation dose dependently (5 to 60 μM) and also inhibits 12(S)-HETE synthesis. Furthermore, Isoxsuprine hydrochloride is the only drug inhibiting the induction of all three mobility markers (MLC2, MYPT and paxillin)[2].
Total infarct volume in vehicle-treated animals is 279±25 mm3 compare to 137±18 mm3 in Isoxsuprine hydrochloride-treated animals[3].
| Catalog Number | R053515 |
| CAS Number | 579-56-6 |
| Synonyms | 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol;hydrochloride |
| Molecular Formula | C18H24ClNO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H23NO3.ClH/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15;/h3-11,13-14,18-21H,12H2,1-2H3;1H |
| InChIKey | QVPSGVSNYPRFAS-UHFFFAOYSA-N |
| SMILES | CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O.Cl |
| Reference | [1]. Falkay G, et al. Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors. J Perinat Med. 1986;14(2):109-13. [2]. Kretschy N, et al. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br J Cancer. 2013 Feb 19;108(3):570-8. [3]. Hill JW, et al. Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One. 2014 May 7;9(5):e96761. |
